Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted): 2023-2025
Historic EPS (Weighted Average and Diluted) for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$2.28.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted) rose 19.72% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.40, marking a year-over-year decrease of 110.40%. This contributed to the annual value of $112.62 for FY2024, which is 649.90% up from last year.
- Latest data reveals that Inhibrx Biosciences reported EPS (Weighted Average and Diluted) of -$2.28 as of Q3 2025, which was down 23.24% from -$1.85 recorded in Q2 2025.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted)'s 5-year high stood at $125.48 during Q2 2024, with a 5-year trough of -$7.29 in Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is $8.93, with a median of -$3.61 in 2023.
- As far as peak fluctuations go, Inhibrx Biosciences' EPS (Weighted Average and Diluted) surged by 2,894.65% in 2024, and later tumbled by 101.47% in 2025.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted) (Quarterly) stood at -$7.29 in 2023, then soared by 38.68% to -$4.47 in 2024, then rose by 19.72% to -$2.28 in 2025.
- Its last three reported values are -$2.28 in Q3 2025, -$1.85 for Q2 2025, and -$2.80 during Q1 2025.